Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms …
H Minderman, Y Zhou, KL O'Loughlin… - Cancer chemotherapy and …, 2007 - Springer
Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of
targeting aberrantly activated NF-κB in AML stem cells. We tested whether bortezomib
cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells. We
also tested whether bortezomib interactions with cytarabine and anthracyclines are affected
by p53, because proteasome inhibition stabilizes p53 and may thus cause cell cycle arrest …
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of
targeting aberrantly activated NF-κB in AML stem cells. We tested whether bortezomib
cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells. We
also tested whether bortezomib interactions with cytarabine and anthracyclines are affected
by p53, because proteasome inhibition stabilizes p53 and may thus cause cell cycle arrest …
Bortezomib activity and in vitro interactions with anthracyclines and cytarabine in acute myeloid leukemia cells are independent of multidrug resistance mechanisms …
M Hans, Y Zhou, L O'Loughlin Kieran… - Cancer Chemotherapy …, 2007 - search.proquest.com
Purpose The proteasome inhibitor bortezomib may be effective in combination with
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of
targeting aberrantly activated NF-κB in AML stem cells. We tested whether bortezomib
cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells. We
also tested whether bortezomib interactions with cytarabine and anthracyclines are affected
by p53, because proteasome inhibition stabilizes p53 and may thus cause cell cycle arrest.
cytarabine and anthracyclines in the treatment of acute myeloid leukemia (AML) by virtue of
targeting aberrantly activated NF-κB in AML stem cells. We tested whether bortezomib
cytotoxicity is affected by multidrug resistance (MDR) proteins expressed in AML cells. We
also tested whether bortezomib interactions with cytarabine and anthracyclines are affected
by p53, because proteasome inhibition stabilizes p53 and may thus cause cell cycle arrest.
以上显示的是最相近的搜索结果。 查看全部搜索结果